



## Therapeutic Potential of *Withania somnifera* in CNS Disorders: A Neuropharmacological Review

Rakesh Kumar Ruhela<sup>1</sup>, Shringika Soni<sup>1</sup> and Bikash Medhi<sup>1\*</sup>

<sup>1</sup>Department of Pharmacology, PGIMER, Chandigarh, India.

### Authors' contributions

This work was carried out in collaboration between all authors. Author RKR designed the study, prepared the figures, wrote the protocol and wrote the first draft of the manuscript. Author SS managed the analyses of the study and the literature searches. All authors read and approved the final manuscript.

### Article Information

DOI: 10.9734/EJMP/2016/24187

#### Editor(s):

- (1) Thomas Efferth, Chair, Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Germany.
- (2) Marcello Iriti, Professor of Plant Biology and Pathology, Department of Agricultural and Environmental Sciences, Milan State University, Italy.

#### Reviewers:

- (1) Mohamed M. Abdel-Daim, Suez Canal University, Ismailia, Egypt.
- (2) Juan Carlos Troiano, University of Buenos Aires, Argentina.
- (3) S. L. Kothari, University of Rajasthan, Jaipur, India.
- (4) B. Ravishankar, SDM Centre for Research in Ayurveda and Allied Sciences SDM College of Ayurveda Campus, India.

Complete Peer review History: <http://www.sciencedomain.org/review-history/15843>

Review Article

Received 8<sup>th</sup> January 2016  
Accepted 27<sup>th</sup> February 2016  
Published 18<sup>th</sup> August 2016

### ABSTRACT

**Context:** According to Ayurveda, the oldest and the first documented system of medicine in the world defines medicinal plants as *Medhya Rasayana* which show properties influencing the brain tissues. *Medhya Rasayana* can reportedly retard brain aging and which help in different central nervous system (CNS) disorders. *Withania somnifera* (Ashwagandha) is one of the *Medhya Rasayana* and it has been shown to have medicinal properties to treat several CNS disorders.

**Objective:** Research in the area of alternative medicine has come up with several options to treat the disorders of CNS. However, a comprehensive review of such a potent medicinal plant; *Withania somnifera* in different CNS disorders has been absent till date. The present review focuses on the effects of phytochemicals isolated from *Withania somnifera* on different types of central nervous system CNS disorders.

**Materials and Methods:** Numerous animal and *in vitro* studies have been conducted on *Withania somnifera*, which advocates strong potential medicinal properties of this plant. We reviewed the

\*Corresponding author: E-mail: [drbikashus@yahoo.com](mailto:drbikashus@yahoo.com);

MEDLINE database to identify experimental studies conducted using *Withania somnifera* in several CNS disorders.

**Results:** Our present study shows that *Withania somnifera* has a very potent role in the treatment of CNS disorders i.e. Parkinson disease, Alzheimer's disease, Epilepsy, Anxiety, OCD, Hypoxia, Huntington's disease, Catalepsy and Bipolar disorder. *Withania somnifera* act on several neurotransmitters to treat these CNS disorders.

**Discussion and Conclusion:** *Withania somnifera* demonstrates remarkable potential in the amelioration of CNS disorders, with anticancer, anti-inflammatory, anti-stress, anti-depressant and anti-anxiety effects.

**Keywords:** *Withania somnifera*; CNS disorders; alternative therapy; Ashwagandha; herbal drug; phyto-therapy.

## 1. INTRODUCTION

*Withania somnifera* (L.) dunal (Ashwagandha), a prolonged used Indian medication has the characteristic of being implanted in *medhya* (related to memory) therapies [1–4].

The perennial shrub of Solanaceae family *W. somnifera*, has gained recognition in the treatment of mental disorders and various health conditions [5]. It has been used for treatment of anxiety [6], neuronal degeneration [7–11] epilepsy, [12-13] depression [14], sleep [15], memory [5,16,17] and so on.

The withanolides have been shown to have anticancer [18-20], anti-inflammatory [21], anti-stress [22], anti-depressant and anti-anxiety effect [23] antioxidant property [24], memory enhancing [25], anti-convulsant [26] and Immune-modulating properties [27].

Ashwagandha is a natural source of alkaloids, steroidal lactones, saponins with an additional acyl group and withanolides with C<sub>6</sub>H<sub>12</sub>O<sub>6</sub> at C-27 position [24] and till now 35 chemical have been discovered, extracted and isolated from roots of WS [28]. The main component of *W. somnifera* is withanolide a derivative of steroids and rich in iron [2].


## 2. COMMON NAME

*W. somnifera* has several common names; Ashwagandha, winter cherry or Indian Ginseng [2]. This plant is known by different names in different part of India; Punir (in Hindi), Aksan (Punjab), Tilli (Marathi), Ashvaganda (Bengal, Bombay) [26]. Other than this, withanolides in *W. somnifera* have structural resemblance with ginsenosides, active chemical compound present

in 'Panax ginseng', therefore it is known as "Indian Ginseng" [29,30].

### 2.1 Biochemical Constituents

In commonly known form of *W. somnifera*, 35 chemicals have been identified and isolated from roots of shrub out of which withanolide A, withanoside IV, and withanoside VI are found to be most active [28] and withaferin A is the most studied component (Fig.1).



**Fig. 1. Structure of an important withanolide of *Withania somnifera* (withaferin A)**

Previous research has demonstrated spectroscopic and physicochemical methods to isolate 5 new derivatives from the roots of Ashwagandha [31]. Several reports have shown the presence of alkaloids, steroidal lactones and saponins also present in minor quantity [9,32]. Apart from these, *W. somnifera* also contains starch, acylsteryl glucosides and amino acids, like tryptophan, alanine, glycine, tyrosine and aspartic acid [9].

Other than withanolide, several alkaloids; choline, pseudo-withanine, somniferine, somnine, tropine, pseudotropine, 3-a-glyoxytropine, isopelletierine and anafarine andanahydrine were also discovered [33,34].

### 3. COMPLEMENTARY AND ALTERNATIVE MEDICINE

Despite of advancements in western medicines, CAM appears to raise ancient medicine towards modern pharmacology that may be considered safer and more effective [35,36]. Chemically synthesized allopathic drugs show adverse effects both physically and economically [37]. Although, many antiepileptic drugs are present to treat epilepsy but many of them show chronic toxicity and teratogenic effects on human brain [38]. Similarly, benzodiazepines prescribed in treatment of bipolar disorder and several psychotic diseases may cause anxiety and insomnia [39,40] if chronically used. Here, the use of alternative medicine comes into picture and absolute demand.

If we talk about CAM in CNS disorders, EEG and neuroimaging techniques have successfully demonstrated the autoregulation and physiology of CAM at par to other established therapies. in CNS and result shows similar structure involvement in different therapeutic approaches [41]. Herbal medications show a holistic approach in the treatment of diseases by lowering or negligible side effects against their synthetic counterparts, which have a reductionist approach [37].

#### 4. *W. somnifera* IN CNS DISEASES

To overcome the therapeutic limitations and side effects of western synthetic medicines [37], herbal treatment is found to be effective in several CNS disorders. *W. somnifera* is widely used to treat diseases from normal infection to cancer [42], but its excessive use in nervous system disorders currently comes in to limelight [24]. Neuromodulation of GABAergic [43,44] or cholinergic pathway [45] are considered elemental in the treatment of CNS disorders via inhibiting excitotoxicity and oxidative damage conditions [46]. We can have a detailed synopsis of the disease as follows.

##### 4.1 Parkinson Disease

Parkinson's disease is most common neurodegenerative disorder in elderly patients [47]. Age, environmental and genetic factors cause loss of dopaminergic neuron leads to tremor, rigidity and postural instability in patients [48-50]. Several studies found that root extract of *W. somnifera* at pharmacological concentration

enhance oxidative status by reducing lipid peroxidation level [51] or by increasing number of TH (Tyrosine hydrolase) positive cell in substantia nigra [10]. *W. somnifera*, 100mg/kg body weight for 7 or 28 days reduced the level of Catecholamines: dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA); antioxidants: glutathione (GSH) and glutathione peroxidase (GPx); and lipid peroxidation marker (TBARS) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced model of PD [11]. In a clinical trail, 18 clinically diagnosed parkinsonian patients were traeted with a concoction in cow's milk of powdered *Mucuna pruriens* and *Hyoscyamus reticulatus* seeds and *W. somnifera* and *Sida cordifolia* roots for 28 days in cleansing therapy and for 56 days in palliative therapy [52]. This study also establishes the necessity of cleansing therapy in Ayurveda medication prior to palliative therapy. Hence *W. somnifera*, could be a promising CAM therapy for Parkinson's disease due to its potential anti-oxidant, anti-peroxidative and free radical quenching properties.

##### 4.2 Alzheimer's Disease

Progressive neurodegenerative Alzheimer's disease (AD) is recognized to cause several abnormalities including memory loss, anxiety, language deficit, depression, mood disturbance and stress [38]. Significant causes of these impairments are cholinergic neuron degeneration, toxic  $\beta$ -Amyloid plaques, neurofibrillary tangles and neurochemical deficiencies [53]. Although, direct target molecule of *W. somnifera* has not been identified yet [54], but root extract of *W. somnifera* shows potential neuroprotective effects against H<sub>2</sub>O<sub>2</sub>- and  $\beta$ -Amyloid cytotoxicity during Alzheimer's disease. Some researchers also believe that dried root abstract of *W. somnifera* enhances liver LRP (low density lipoprotein receptor- related protein) and decreases  $\beta$ -Amyloid formation by A $\beta$ -degrading protease neprilysin (NEP) in brain [55]. There are lots of active ingredients of WS but few are very active like withanolide A, withanoside IV, and withanoside VI. Role of these ingredients in neurodegenerative diseases have been reported as they improve memory impairment, neurite atrophy, and synaptic loss in the cerebral cortex by restoring presynapses and postsynapses both In axons and dendrites in cortical neurons. The effect of the *W. somnifera* has been found both in neurons as well as in glial cells. Further studies on Ashwagandha may lead

to important leads which may help to solve urgent need in AD treatment.

### 4.3 Epilepsy

The metabolic profile of *W. somnifera* includes restoration of imbalance in GABA / glutamate modulation [56] and higher serum level of peptide hormone, Ghrelin [57]. Despite the availability of anti-epileptic drugs, either the cost or difficulty to access with physicians [58] or adverse side effect of AED[59] make allopathic drugs less concerned in epilepsy. *W. somnifera* acting as CAM in epilepsy treatment [60] shows antioxidative mechanism, increasing GABA level & cortical muscarinic ACh and enhances neurite regeneration in brain [5]. This inexpensive and culturally acceptable herbal therapy may open new doors for epileptic patients around the world [60].

### 4.4 Anxiety

It's widespread psychopathological disorder associated with unpleasant emotional state shows lifetime prevalence leads to depression, somatic distress and low self-esteem [6,61]. Neurotonic effect of root withanolides produces GABA-mimetic activity in treatment of anxiety [43,62]. Still, unidentified dosing of *W. somnifera* may cause intolerable side effects on humans [63].

### 4.5 OCD

This mental disorder characterized by persistent and distressed thought (Obsessions) with repeated egoistic behavior (compulsion) [64]. It causes impairment in serotonergic & dopaminergic system [65,66] with pathological defects, observed in orbitofrontal cortex, dorsolateral PFC and ant. cingulate cortex [67]. WS possess anxiolytic & anti-depressant properties, therefore considered in OCD treatment [64]. Methanolic and aqueous root extract of Ashwagandha increases serotonergic transmission [14,64] via effecting 5HT<sub>2A/2C</sub> receptors in brain.

### 4.6 Hypoxia

Hypoxia is considered to generate superoxide radicals because of less availability of oxygen [68] which causes hippocampal neuro-degeneration and cognitive dysfunction including memory impairment [69,70]. Withanolide A maintains balance of corticosterone level by increasing mineralocorticoid receptor expression

and decreasing glucocorticoid expression in hippocampus. This signalling pathway plays a vital role in memory and neuronal survivability [70].

### 4.7 Huntington's Disease

HD is also a neurodegenerative disease identified by neuronal destruction in basal ganglia [71] accompanied by progressive motor dysfunction, chorea, dystonia, emotional disturbances, memory, and weight loss [72]. HD can be induced by introducing oxidative stress factor (i.e. 3-Nitropropionic acid) in experimental animals. In pathophysiology of the HD; GABA and enkephalin neurons of basal ganglia plays an important role [38,73] along with molecular alteration in (NMDA) receptors [74]. Polyglutamine stretches formed by Cytosine-Adenine-Guanine (CAG) repeats with the increasing age is highly correlated with the HD.

*W. somnifera* acts on GABAergic system aberrance, this is a major cause of most of neurological disorders. WS root extract corrects the major imbalance in GABAergic system and improves cognitive function, acetyl cholinesterase enzyme activity and glutathione enzyme level in experimental animal model of HD. Treatment with *W. somnifera* restores impaired motor function and other cognitive deficits. The antioxidant property of the WS root extract makes it a potential leader to treat HD [75].

### 4.8 Catalepsy

Neuroleptic catalepsy can be reversed by D1 & D2 receptor agonist [76] and *W. somnifera* play an important role in this as with combination of other drugs, NR-ANX-C (*W. somnifera*, *Ocimum sanctum*, *Camellia sinensis*, *triphala* and *shilajit*) [77].

### 4.9 Bipolar Disorder

Cognitive impairments with frequent mood fluctuations are easily observed in bipolar disorder [78]. Anxiety and insomnia are commonly observed symptoms [39,79] in this disorder. Limited treatment availability makes herbal medication an attractive tool [80]. Very few studies of *W. somnifera* on bipolar disorder reported functional recovery in patients [81]. A reduction in insomnia and anxiety condition with auditory-verbal working memory improvement also observed in *W. somnifera* treated subjects [82].

**Table 1. Important studies on few of CNS disorders, their model, type of treatment, doses, time of treatment, evaluated parameters and results**

S. no.	Disease	Inducer	Treatment	Dose	Treatment duration	Evaluated parameters	Result	Ref.
1.	PD	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)	<i>Withania somnifera</i> root extract	100 mg/kg body weight	7 or 28 days	DA, DOPAC, HVA, GSH and GPx	Reduced levels of DA, DOPAC, HVA, GSH and GPx.	[11]
2.	PD	6-Hydroxydopamine (6-OHDA)	<i>Withania somnifera</i> extract	100, 200 and 300 mg/kg body weight	3 weeks	Lipidperoxidation, reduced glutathione content, activities of glutathione-S-transferase, glutathione reductase, glutathione peroxidase, superoxide dismutase and catalase, catecholamine content, dopaminergic D2 receptor binding and tyrosine hydroxylase expression	Reverse all the parameters significantly.	[84]
3.	PD	1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP; i.p, 20 mg/kg body weight for 4 days),	<i>Withania somnifera</i> (Ws) root extract	100 mg/kg body weight	4 weeks	Thiobarbituric acid reactive substance (TBARS), and increased activities of superoxide dismutase (SOD) and catalase (CAT)	Significant improvement in the mice's behavior and antioxidant status, along with a significant reduction in the level of lipid peroxidation.	[51]
4.	Alzheimer's disease	APP/PS1 Alzheimer's disease transgenic mice.	WS extract	1 g/kg	7-30 days	Plasma and brain A $\beta$ , Behavioral Deficits and Plaque Pathology	Reversed behavioral deficits, plaque pathology, accumulation of $\beta$ -amyloid peptides (A $\beta$ ) and oligomers in the brains of middle-aged and old APP/PS1 Alzheimer's disease transgenic mice.	[55]
5.	Epilepsy	PTZ	WS extract	100 or 200 mg/kg,	-	Seizure threshold	Increased the seizure threshold	[5]
6.	Hypoxia	Simulated altitude of 25,000 ft	<i>Withania somnifera</i> root extract	10 $\mu$ mol/kg	21 days pre-exposure and during 07 days of	Expression of GCLC and Nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2) and glutathione (GSH) level .	Suppressed Nrf2 and GCLC expression whereas inhibition of corticosterone synthesis upregulated Nrf2	[70]

S. no.	Disease	Inducer	Treatment	Dose	Treatment duration	Evaluated parameters	Result	Ref.
					exposure to a simulated altitude of 25,000 ft		as well as GCLC	
7.	Obsessive compulsive disorder	Marble-burying behavior	Methanolic extract <i>W. somnifera</i>	10, 25, 50, 100 mg/kg	30 min. prior to the assessment	Marble burying behavior	Successively decreased the marble burying behavior activity without affecting motor activity	[64]
8.	Catalepsy	Haloperidol (1mg/kg)	NR-ANX-C, a polyherbal formulation containing bioactives of <i>Withania somnifera</i> , <i>Ocimum sanctum</i> , <i>Camellia sinensis</i> , triphala and shilajit	25 mg/kg		The superoxide dismutase (SOD) level in brain tissue	Significant (P<0.01) reduction in the cataleptic scores and reduction in SOD activity was observed in NR-ANX-C (25 and 50 mg/kg) treated groups	[77]



**Fig. 2. *Withania somnifera* acts on different molecular parameters to treat several CNS disorders**

## 5. CONCLUSION

CNS disorders are one of the major threats of modern life and are considered as the most disabling disease which is a big burden on the society. Millions of people every year are disabled with different types of CNS disorders despite tremendous efforts to find methods to control and cure. Although great advances have been made in modern medical science to control disease but many diseases like Autism are not yet curable [83]. The underlying mechanism leading up to CNS disorders are still unknown and most of them remain a mysterious. To find out newer, safer and effective therapeutics, scientists are evaluating some medicinal plants and herbs which are rich source for a variety of chemicals with nutritive and therapeutic properties. World-over the pharmaceutical companies and research organizations are focusing on the vast untapped potential of herbs as potent drugs.

*W. somnifera* demonstrates remarkable potential in the amelioration of CNS disorders, with anticancer, anti-inflammatory, anti-stress, anti-depressant and anti-anxiety effects. The results of some powerful studies indicated that at least part of the chronic stress-induced pathology may be due to oxidative stress, which is mitigated by

*W. somnifera* [84]. Use of alternative medicine is growing as the side effects of allopathic medicine are increasing. In such conditions biomedical research on *W. somnifera* can open new gates towards the treatment of CNS and other disorders.

*W. somnifera* is an ingredient in many formulations prescribed for a variety of musculoskeletal conditions (e.g., arthritis, rheumatism), and as a general tonic to increase energy, improve overall health and longevity, and prevent disease in athletes, the elderly, and during pregnancy [85,86]. WS is well known for its other biological activities like anti-parkinsonism [48-50], anti- Alzheimer's [54,55], anti-epileptic [59,60], anti-anxiety [43,62], anti-Huntington [73,74] and anti-catalepsy [77]. Important studies using *W. somnifera* have been listed in Table 1 and the results of the studies described in Table 1 show its chemical ingredients are effective in prevention and treatment of different kinds of CNS disorder like Parkinson, epilepsy, Huntington and bipolar disorder (Fig. 2 above).

Therefore, the use of *W. somnifera* as multi-dimensional traditional medicine has resulted into several commercial drugs and therefore *W. somnifera* ranks as a valuable plant in the

pharmaceutical industries. This medicinal plant *W. somnifera* alone can be used as complementary and alternative medicine (CAM) in the treatment of CNS disorders. All the described studies shows that the *W. somnifera* work as adaptogen/ anti-stress agent, immunomodulator, antioxidant (reducing free radical damage, anabolic effect, improving resistance of the body, reducing fatigue and detoxificant effects makes it the best complementary and alternative medicine (CAM). Although, the phyto-chemistry and pharmacology of *W. somnifera* has been widely investigated in several diseases, yet the studies on protective effect of the extracts of the plant parts in different neurodevelopmental disorders are very few. Although it is required to identify the novel clinical properties of the plant in case of some neurodevelopmental disorders like autism spectrum disorder, the severe disorder in which the drug therapy is very limited.

Here, we are able to suggest that the other diseases which happens due to or result in imbalance in above said mechanism like autism spectrum disorder (ASD), *W. somnifera* may be very useful.

## 6. FUTURE PERSPECTIVE

Complexity of CNS disorders and many adverse effect of western medicine highly support herbal drug therapy in future. The use of *W. somnifera* as multi-dimensional traditional medicine has resulted into several commercial drugs and therefore *W. somnifera* ranks a valuable plant in the pharmaceutical industries. The phyto-chemicals and pharmacology of *W. somnifera* has been widely investigated in several diseases. Beside the CNS disorders we discussed in this review, there are numbers of CNS disorder on which the studies on protective effect of the extracts of the plant parts are not tested i.e. dementia, autism and other neurodevelopmental disorders. Although it is required to identify the novel clinical properties of the plant in case of some neurodevelopmental disorders like autism spectrum disorder, the severe disorder in which the drug therapy is very limited. Still lots of research are required to fully characterize the mechanism of action in CNS disorders of phyto-chemicals of *W. somnifera*.

## CONSENT

It is not applicable.

## ETHICAL APPROVAL

It is not applicable.

## ACKNOWLEDGEMENT

This research was supported by a grant from the Department of Biotechnology, Govt. of India.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Bhatnagar M, Sharma D, Salvi M. Neuroprotective effects of *Withania somnifera dunal.*: A possible mechanism. *Neurochem Res.* 2009;34(11):1975–1983.
2. Singh G, Sharma PK, Dudhe R, Singh S. Biological activities of *Withania somnifera*. *Ann. Biol. Res.* 2010;1(3):56–63.
3. Kataria H, Wadhwa R, Kaul SC, Kaur G. Water extract from the leaves of *Withania somnifera* protect RA differentiated C6 and IMR-32 cells against glutamate-induced excitotoxicity. *PLoS One.* 2012;7(5): e37080.
4. Vayalil PK, Kuttan G, Kuttan R. Rasayanas: Evidence for the concept of prevention of diseases. *Am J Chin Med.* 2002;30(1):155–171.
5. Kulkarni SK, Dhir A. *Withania somnifera*: An Indian ginseng. *Prog Neuro-psychopharmacol Biol Psychiatry.* 2008;32(5):1093–1105.
6. Gupta V, Bansal P, Kumar S, Sannd R, Rao MM. Therapeutic efficacy of phytochemicals as anti-anxiety - A Review. *J Pharm Res.* 2010;31:174–179.
7. Kumar S, Seal CJ, Howes MJR, Kite GC, Okello EJ. *In vitro* protective effects of *Withania somnifera (L.) dunal* root extract against hydrogen peroxide and  $\beta$ -amyloid(1-42)-induced cytotoxicity in differentiated PC12 cells. *Phytother Res.* 2010;24(10):1567–7154.
8. Tohda C, Kuboyama T, Komatsu K. Search for natural products related to regeneration of the neuronal network. *Neurosignals.* 2005;14(1–2):34–45.
9. Rana A, Gupta GL. *Withania somnifera* Ashwagandha: A review. *Phcog Rev.* 2007;1(129).

10. Prakash J, Yadav SK, Chouhan S, Singh SP. Neuroprotective role of *Withania somnifera* root extract in maneb-paraquat induced mouse model of parkinsonism. *Neurochem Res.* 2013;8(5):972–980.
11. RajaSankar S, Manivasagam T, Sankar V, Prakash S, Muthusamy R, Krishnamurti A, et al. *Withania somnifera* root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse. *J Ethnopharmacol.* 2009;125(3):369–373.
12. Moharana S, Moharana D. A clinical trial of mentat in patients with various types of epilepsy. *Probe (Lond).* 1994;33:160–162.
13. Ahemed T, Hasan S, Dwivedi V, Mishra M, Singh PK, Hashmi F. Anti epileptic activity of some medicinal plants. *Int J Med Arom Plants.* 2012;22:354–360.
14. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Anxiolytic-antidepressant activity of *Withania somnifera* glycowithanolides: An experimental study. *Phytomedicine.* 2000;7(6):463–469.
15. Farag NH, Mills PJ. A randomised-controlled trial of the effects of a traditional herbal supplement on sleep onset insomnia. *Complement Ther Med.* 2003; 11(4):223–225.
16. Ghosal US, Lal J, Srivastava R, Bhattacharya SK. Immunomodulatory and CNS effects of sitoindosides IX and X two new glycowithanolides from *Withania somnifera*. *Phytother Res.* 1989;3:201–206.
17. Tohda C, Joyashiki E. Sominone enhances neurite outgrowth and spatial memory mediated by the neurotrophic factor receptor, RET. *Br J Pharmacol.* 2009; 157(8):1427–1440.
18. Subbaraju GV, Vanisree M, Rao CV, Sivaramakrishna C, Sridhar P, Jayaprakasam B, et al. Ashwagandhanolide, a bioactive dimeric thiowithanolide isolated from the roots of *Withania somnifera*. *J Nat Prod.* 2006;69(12):1790–1792.
19. Winters M. Ancient medicine, modern use: *Withania somnifera* and its potential role in integrative oncology. *Altern Med Rev.* 2006;11(4):269–277.
20. Stan SD, Zeng Y, Singh SV. Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. *Nutr Cancer.* 2008;60(Suppl 1)(23):51–60.
21. Davis L, Kuttan G. Effect of *Withania somnifera* on cell mediated immune responses in mice. *J Exp Clin Cancer Res.* 2002;21(4):585–590.
22. Rai D, Bhatia G, Sen T, Palit G. Anti-stress effects of *Ginkgo biloba* and *Panax ginseng*: A comparative study. *J Pharmacol Sci.* 2003;93(40):458–464.
23. Archana R, Namasivayam A. Antistressor effect of *Withania somnifera*. *J Ethnopharmacol.* 1998;64(1):91–93.
24. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of *Withania somnifera* (ashwagandha): A review. *Altern Med Rev.* 2000;5(4):334–346.
25. Verma A, Kulkarni SK. Ashwagandha and Bramhi: Nootropic and de-addiction profile of psychotropic indigenous plants. *Drugs Today.* 1993;29:257–263.
26. Kulkarni SK, Akula KK, Dhir A. Effect of *Withania somnifera* Dunal root extract against pentylenetetrazol seizure threshold in mice: Possible involvement of GABAergic system. *Indian J Exp Biol.* 2008;46(6):465–469.
27. Davis L, Kuttan G. Immunomodulatory activity of *Withania somnifera*. *J Ethnopharmacol.* 2000;71(1–2):193–200.
28. Mehrotra BN, Rastogi RP. Compendium of Indian Medicinal Plants. Vol. 6. Central Drug Research Institute, Lucknow: Publications and Information Directorate, Lucknow; 1998.
29. Grandhi A, Mujumdar AM, Patwardhan B. A comparative pharmacological investigation of Ashwagandha and Ginseng. *J Ethnopharmacol.* 1994;44(3):131–135.
30. Singh B, Saxena AK, Chandan BK, Gupta DK, Bhutani KK, Anand KK. Adaptogenic activity of a novel, withanolide-free aqueous fraction from the roots of *Withania somnifera* Dun. *Phytother Res.* 2001; 15(4):311–318.
31. Zhao J, Nakamura N, Hattori M, Kuboyama T, Tohda C, Komatsu K. Withanolide derivatives from the roots of *Withania somnifera* and their neurite outgrowth activities. *Chem Pharm Bul. (Tokyo).* 2002;50(6):760–765.
32. Gupta MM, Gupta AP, Verma RK, Misra HO. Quantitative determination of withaferin A in different plant parts of *Withania somnifera* by TLC densitometry. *J Med Aromat Plant Sci.* 1996;18:788–790.
33. Elsakka M, Grigorescu E, Stanescu U, Dorneanu V. New data referring to

- chemistry of *Withania somnifera* species. Rev Med Chir Soc Med Nat Iasi. 1990;94(2):385–387.
34. Bone K. Clinical applications of ayurvedic and Chinese herbs. Warwick: Phytotherapy Press. 1996;137–141.
  35. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med. 2001;135(8-II):594–600.
  36. Reilly D. Comments on complementary and alternative medicine in Europe. J Altern Complement Med. 2001;7(Suppl 1): S23–S31.
  37. Verma S, Singh SP. Current and future status of herbal medicines. Vet World. 2008;1(11):347–350.
  38. Kumar SA, Babu BH, Lakshmi MS. A review on traditional system of medicine for treats epilepsy. Int J Biol Pharm Res. 2010;11:1–6.
  39. Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, et al. Prospective 12-month course of bipolar disorder in outpatients with and without comorbid anxiety disorders. Br J Psychiatry. 2006;189:20–25.
  40. Uzun S, Kozumplik O, Jakovljevic M, Sedic B. Side effects of treatment with benzodiazepines. Psychiatr Danub. 2010; 22(1):90–93.
  41. Esch T, Guarna M, Bianchi E. Commonalities in the central nervous system's involvement with complementary medical therapies: Limbic morphinergic processes. Med Sci Monit. 2004;10(6):6–17.
  42. Yamada K, Hung P, Park TK, Park PJ, Lim BO. A comparison of the immunostimulatory effects of the medicinal herbs Echinacea, Ashwagandha and Brahmi. J Ethnopharmacol. 2011;137(1): 231–235.
  43. Mehta AK, Binkley P, Gandhi SS, Ticku MK. Pharmacological effects of *Withania somnifera* root extract on GABAA receptor complex. Indian J Med Res. 1991;94:312–315.
  44. George B, Kulkarni SK. Anticonvulsant action of *Withania somnifera* Ashwagandha root extract against pentylenetetrazol-induced kindling in mice. Phytother Res. 1996;10:447–449.
  45. Schliebs R, Liebmann A, Bhattacharya S, Kumar A, Ghosal S, Bigl V. Systemic administration of defined extracts from *Withania somnifera* (Indian ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. Neurochem Int. 1997;30(2):181–190.
  46. Parihar MS, Hemnani T. Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. J Biosci. 2003;28(1): 121–128.
  47. Dauer W, Przedborski S. Parkinson's Disease: Mechanisms and models. Neuron. 2003;39(6):889–909.
  48. Singh N, Pillay V, Choonara YE. Advances in the treatment of Parkinson's disease. Prog Neurobiol. 2007;81(1):29–44.
  49. Mounsey RB, Teismann P. Mitochondrial dysfunction in Parkinson's disease: Pathogenesis and neuroprotection. Parkinsons Dis. 2010;2011:617472.
  50. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol. 2000;7(4),Suppl 1:S2–S9; discussion S9–S11.
  51. Sankar SR, Manivasagam T, Krishnamurti A, Ramanathan M. The neuroprotective effect of *Withania somnifera* root extract in MPTP-intoxicated mice: An analysis of behavioural and biochemical variables. Cell Mol Biol Lett. 2007;12:473–481.
  52. Nagashayana N, Sankarankutty P, Nampoothiri MRV, Mohan PK, Mohanakumar KP. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. J Neurol Sci. 2000;176:124–127.
  53. Ross C, Poirier M. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10:S10–S17.
  54. Komatsu K, Kuboyama T, Tohda C. Effects of Ashwagandha Roots of *Withania somnifera* on neurodegenerative diseases. Biol Pharm Bull. 2014;376:892–897.
  55. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, et al. *Withania somnifera* reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA. 2012;109(9): 3510–3515.
  56. Sierra-Paredes G, Sierra-Marcuño G. Extrasynaptic GABA and glutamate receptors in epilepsy. CNS Neurol Disord Drug Targets. 2007;6(4):288–300.
  57. Berilgen MS, Mungen B, Ustundag B, Demir C. Serum ghrelin levels are enhanced in patients with epilepsy. Seizure. 2006;15(2):106–111.

58. Meinardi H, Scott R, Reis R, Sander JWaS. The treatment gap in epilepsy: The current situation and ways forward. *Epilepsia*. 2001;42(1):136–149.
59. Brodie MJ. Diagnosing and predicting refractory epilepsy. *Acta Neurol Scand Suppl*. 2005;181(17):36–39.
60. Schachter SC. Botanicals and herbs: A traditional approach to treating epilepsy. *Neurotherapeutics*. 2009;6(2):415–420.
61. Pratte MA, Nanavati KB, Young V, Morley CP. An alternative treatment for anxiety: A systematic review of human trial results reported for the ayurvedic herb *Ashwagandha (Withania somnifera)*. *J Altern Complement Med*. 2014;20(12):901–908.
62. Ticku MK, Kulkarni SK, Sharma A, Verma A. GABA receptor mediated anticonvulsant action of *Withania somnifera* root extract. *Indian Drugs*. 1993;30:305–312.
63. Thatcher GW, Cates M, Wells BG. Anxiety disorders. In: Herfindal ET, Gourley DR, Ed. *Therapeutics Drug and Disease Management*. Baltimore: Williams and Wilkins. 1996;1073–1093.
64. Kaurav Bhanu PS, Wanjari MM, Chandekar A, Chauhan NS, Upmanyu N. Influence of *Withania somnifera* on obsessive compulsive disorder in mice. *Asian Pac J Trop Med*. 2012;5(5):380–384.
65. Denys D, Dijk AV, Klomp makers A. Role of serotonin in obsessive-compulsive disorder. *Futur*. 2008;35:589–603.
66. Koo MS, Kim EJ, Roh D, Kim CH. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. *Expert Rev Neurother*. 2010;10(2):275–290.
67. Eisen JL, Phillips K, Coles ME, Rasmussen S. Insight in obsessive compulsive disorder and body dysmorphic disorder. *Compr Psychiatry*. 2004;45(1):10–15.
68. Won SJ, Kim DY, Gwag BJ. Cellular and molecular pathways of ischemic neuronal death. *J Biochem Mol Biol*. 2002;35(1):67–86.
69. Bahrke MS, Shukitt-hale B. Effects of altitude on mood, behaviour and cognitive functioning: A review. *Sport Med*. 1993;16(2):97–125.
70. Baitharu I, Jain V, Deep SN, Shroff S, Sahu JK, Naik PK, Ilavazhagan G. Withanolide A prevents neurodegeneration by modulating hippocampal glutathione biosynthesis during Hypoxia. *PLoS One*. 2014;9(10):1–17.
71. Tasset I, Sánchez-López F, Agüera E, Fernández-Bolaños R, Sánchez FM, Cruz-Guerrero A, Gascón-Luna F, Túnez I. NGF and nitrosative stress in patients with Huntington's disease. *J Neurol Sci*. 2012;315(1–2):133–136.
72. Kumar P, Kalonia H, Kumar A. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: Protective effect of licofelone. *Br J Pharmacol*. 2011;164(2b):644–654.
73. Zadori D, Geisz A, Vamos E, Vecsei L, Klivenyi P. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. *Pharmacol Biochem Behav*. 2009;94(1):148–153.
74. Ellerby LM. Hunting for excitement: NMDA receptors in Huntington's disease. *Neuron*. 2002;33(6):841–842.
75. Kumar P, Kumar A. Possible neuroprotective effect of *Withania somnifera* root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease. *J Med Food*. 2009;12(3):591–600.
76. Bever, Janssen PAJ, Van WFM. Springer: *Hand book of psychopharmacology: Neuroleptics and Schizophrenia*. New York; 1978.
77. Nair SV, Arjuman A, Dorababu P, Gopalakrishna HN, Rao UC, Mohan L. Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice. *Indian J Med Res*. 2007;126(5):480–484.
78. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon D, Leon AC, Rice J, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. *Arch Gen Psychiatry*. 2002;59(6):530–537.
79. Putnins SI, Griffin ML, Fitzmaurice GM, Dodd DR, Weiss RD. Poor sleep at baseline predicts worse mood outcomes in patients with co-occurring bipolar disorder and substance dependence. *J Clin Psychiatry*. 2012;73(5):703–708.
80. Spinella M, Eaton L. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. *Brain Inj*. 2002;16(4):359–367.

81. Chengappa KNR, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R. Randomized placebo-controlled adjunctive study of an extract of *Withania somnifera* for cognitive dysfunction in bipolar disorder. *J Clin Psychiatry*. 2013;74(11):1076–1083.
82. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. *Eur Neuropsychopharmacol*. 2011;21(12):841–860.
83. Ruhela RK, Prakash A, Medhi B. An urgent need for experimental animal model of autism in drug development. *Ann Neurosci*. 2015;22(1):44-9.
84. Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, Islam F. Neuroprotective effects of *Withania somnifera* on 6-hydroxydopamine induced Parkinsonism in rats. *Hum Exp Toxicol*. 2005;24(3):137-47.
85. Jain R, Kachhwaha S, Kothari SL. Phytochemistry, pharmacology, and biotechnology of *Withania somnifera* and *Withania coagulans*: A review. *J Med Plant Res*. 2012;6:5388-5399.
86. Singh N, Verma P, Pandey BR, Gilca M. Role of *Withania somnifera* in prevention and treatment of cancer: An overview. *Int. J Pharm Sci Drug Res*. 2011;3(4):274-279.

© 2016 Ruhela et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:  
<http://sciedomain.org/review-history/15843>